PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages

  Cui, Bo ^a   Yang, Qi ^a   Guan, Haixia ^b   Shi, Bingyin ^a   Hou, Peng ^a   Ji, Meiju ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; ANTINEOPLASTIC AGENT; HISTONE H3; PRIMA 1; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER CELL DESTRUCTION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; GENE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; TP53 GENE; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE;

ADENOSINE; ANIMALS; APOPTOSIS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MICE; MICE, NUDE; MUTANT PROTEINS; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902338082     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3147     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90
2. Burns WR, Zeiger MA. Differentiated thyroid cancer. Semin Oncol. 2010;37:557-566.
3. Cornett WR,Sharma AK,Day TA,et al Anaplastic thyroid carcinoma: an overview Curr Oncol Rep. 2007 9 152-158.
4. WeinRO,WeberRS. Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg. 2011;19:113-118.
5. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006;13:119-128.
6. XingM.Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184-199.
7. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
8. Borbone E, Troncone G, Ferraro A, et al. Enhancer of zeste homolog 2 overexpressio n has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:1029-1038.
9. Esposito F, Tornincasa M, Pallante P, et al. Down-regulation of the miR-25 and mi R-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012;97:E710-E718.
10. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21-29.
11. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039-1043.
12. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17:2613-2618.
13. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050-1063.
14. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced byDNAmethylation. Mol Cancer Ther. 2009;8:1579-1588.
15. FiskusW,WangY, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferaseEZH2inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2 009;114:2733-2743.
16. Gannon OM, Merida de Long L, Endo-Munoz L, et al. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res. 2013;19:428-441.
17. Kemp CD, Rao M, Xi S, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res. 2012;18: 77-90.
18. Crea F, Hurt EM, Mathews LA, et al. Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011;10:40.
19. Hayden A, Johnson PW, Packham G, Crabb SJ. S-Adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhib ition. Breast Cancer Res Treat. 2011;127:109-119.
20. Cheng LL, Itahana Y, Lei ZD, et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res. 2012;18:4201-4212.
21. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer. 2009;9:773-784.
22. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846-856.
23. Varambally S, Dhanasekaran SM , Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-629.
24. Xie Z, Bi C, Cheong LL, et al. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One. 2011;6: e21583.
25. Puppe J,Drost R,Liu X,et al BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and se nsitive to polycomb repressive complex 2-inhibitor 3-deazaneplanocin A Breast Cancer Res. 2009 11 R63.
26. Lane D. Curing cancer with p53. N Engl J Med. 2004;350:2711-2712.
27. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594-604.
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
29. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607-614.
30. Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest. 2001;24:536-545.
31. OlivierM,Langero d A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12:1157-1167.
32. Fagin JA.Tumorsuppressor genes inhumanthyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J Endocrinol Invest. 1995;18:140-142.
33. Gauchotte G, Philippe C, Lacomme S, et al. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology. 2011;43:447-452.
34. Messina RL, Sanfilippo M, Vella V, et al. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer. 2012;130:2259-2270.
35. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15:376-388.
36. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009;1:a001883.